Soluble guanylate cyclase activators

US8895583B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• John Qiang Tan · New Brunswick, US
• Ronald Kim · Essen, DE
• John W. Mirc · Tokyo, JP

Key dates

• Filing date: Oct 24, 2011
• Grant date: Nov 25, 2014
• Expiry date: Oct 24, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.